Class Action Lawsuit Notification for Pacira BioSciences
The Gross Law Firm provides an important notice for shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX).
All shareholders who acquired shares of PCRX during the specified class period are encouraged to get in touch with the firm about the opportunity for a lead plaintiff appointment. It is worth noting that being appointed as a lead plaintiff is not necessary to seek any recovery.
Understanding the Class Period
CLASS PERIOD: The relevant time frame extends from August 2, 2023, to August 8, 2024.
Allegations and Background
According to the complaint, Pacira BioSciences encountered issues with their patent claims. On August 9, 2024, a significant announcement came from the company regarding a lawsuit against eVenus for patent infringement. The company revealed that a court had declared their U.S. Patent No. 11,033,495 (the '495 patent) invalid, indicating that eVenus was not infringing on the patent. The '495 patent is crucial for Exparel, the major revenue generator for the company, contributing to around 80% of its overall income.
This development raised concerns among analysts regarding the sustainability of Pacira's other patents. Analysts highlighted the risk of seeing more generic competitors entering the market and facing increased litigation costs moving forward. Following this alarming news, Pacira's stock price experienced a steep decline, plummeting from $22.36 per share on August 8, 2024, to a low of $11.70 per share the very next day – a staggering drop of over 47%. This sharp decrease reflects the impact of negative legal news on investor confidence.
Registration Deadline Information
DEADLINE: Shareholders must not hesitate to register for this class action, with the cut-off date set for March 14, 2025. All interested individuals can secure their place by registering their information through designated channels.
Steps for Shareholders
NEXT STEPS FOR SHAREHOLDERS: If you qualify as a shareholder who purchased shares of PCRX during the class period, you will benefit from a portfolio monitoring service that keeps you informed about the case's progress. While the deadline to pursue the role of lead plaintiff is March 14, 2025, it's important to emphasize that involvement in this case requires no financial commitment.
Why Trust the Gross Law Firm?
The Gross Law Firm is a well-known class action law firm dedicated to the needs of investors who have suffered due to deceptive practices and unlawful business methods. Their primary mission centers on ensuring that companies uphold ethical business practices and recognize their responsibilities toward investors. The firm aims to provide justice and recover losses for investors affected by misleading statements or failure to disclose vital information that artificially inflated stock values. It’s important to remember that past outcomes do not guarantee similar future results.
Contact Information
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY 10018
Phone: (646) 453-8903
Frequently Asked Questions
What is the class period for the Pacira BioSciences lawsuit?
The class period for this lawsuit spans from August 2, 2023, to August 8, 2024.
How can I register for the class action?
Shareholders are encouraged to register their information through the provided channels before the March 14, 2025 deadline.
What is the significance of the U.S. Patent No. 11,033,495?
The invalidity of U.S. Patent No. 11,033,495 significantly affects Pacira's revenue streams, particularly from Exparel, which accounts for a major portion of its income.
What actions did Pacira take after the patent was ruled invalid?
In response to the ruling, Pacira BioSciences communicated the details through a press release, leading to a substantial drop in their stock price.
Is there any cost to participate in the lawsuit?
No, there is no cost associated with participating in the class action lawsuit.
